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Summary. The goal of the present work was to evaluate
the correlation of glucose transporter 1 (GLUT1) and
carbonic anhydrase IX (CAIX) with the
monocarboxylate transporters 1 (MCT1) and 4 (MCT4)
and their chaperone, CD147, in breast cancer. The
clinico-pathological value of GLUT1 and CAIX was
also evaluated. For that, we analysed the
immunohistochemical expression of GLUT1 and CAIX,
in a large series of invasive breast carcinoma samples
(n=124), previously characterized for MCT1, MCT4 and
CD147 expression. GLUT1 expression was found in
46% of the cases (57/124), while CAIX was found in
18% of the cases (22/122). Importantly, both MCT1 and
CD147, but not MCT4, were associated with GLUT1
and CAIX expression. Also, GLUT1 and CAIX
correlated with each other. Concerning the clinico-
pathological values, GLUT1 was associated with high
grade tumours, basal-like subtype, absence of
progesterone receptor, presence of vimentin and high
proliferative index as measured by Ki-67. Additionally,
CAIX was associated with large tumour size, high
histological grade, basal-like subtype, absence of
estrogen and progesterone receptors and presence of
basal cytokeratins and vimentin expression. Finally,
patients with CAIX positive tumours had a significantly
shorter disease-free survival. 
The association between MCT1 and both GLUT1
and CAIX may result from hypoxia-mediated metabolic
adaptations, which confer a glycolytic, acid-resistant and
more aggressive phenotype to cancer cells.
Key words: GLUT1, CAIX, Monocarboxylate
transporters (MCTs), CD147/EMMPRIN, Breast
carcinoma, Immunohistochemistry
Introduction
Early epithelial carcinogenesis occurs under hypoxic
conditions, since altered cells are separated from the
vascularised stroma, source of oxygen and nutrients. To
maintain the needed ATP levels, cancer cells increase
their rates of glycolysis, acquiring a significant
proliferative advantage. However, this phenotype leads
to an overload of lactic acid, which must be exported
from the cell, causing a decrease in the extracellular pH. 
Constitutive upregulation of glycolysis requires
additional adaptations, namely, resistance to apoptosis
and upregulation of membrane transporters to maintain
normal intracellular pH (Gatenby and Gilles, 2004). The
need to increase glucose uptake, to allow high glucose
consumption rates, is achieved by upregulation of
glucose transporters (GLUT) in the plasma membrane of
cancer cells, especially the hypoxia-responsive GLUT1
(Ganapathy et al., 2009). However, the role of GLUT1 in
breast cancer remains poorly elucidated (Younes et al.,
1995; Kang et al., 2002).
Besides being an adaptation to high glycolytic
phenotype, the acidic environment represents, per se, a
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significant advantage for tumour cells since it is
associated with increased migration, invasion and
metastases, among others (Gatenby and Gilles, 2004;
Gatenby et al., 2006). Although lactate produced by
glycolysis under hypoxic conditions is a significant
contributor to acidic extracellular pH, there is also a
substantial contribution from carbonic acid (Helmlinger
et al., 2002). In this context, the hypoxia-responsive
carbonic anhydrase isoforms, CAIX and CAXII, emerge
as important contributors to the regulation of cancer cell
intracellular pH (Swietach et al., 2007; Chiche et al.,
2009), with CAIX, in particular, being associated with
poor prognosis in breast cancer (Chia et al., 2001;
Trastour et al., 2007; Hussain et al., 2007; Tan et al.,
2009; Chen et al., 2010). 
Another important group of proteins involved in
intracellular pH regulation are monocarboxylate
transporters (MCTs), which are also responsible for
transmembrane transport of lactate (Izumi et al., 2003).
By performing these two inter-dependent activities
(lactate transport coupled with a proton), MCTs appear
as strong potential targets for cancer therapy. Indeed,
there is evidence for the up-regulation of MCTs in
tumours, such as high grade glial neoplasms (Mathupala
et al., 2004), colorectal (Koukourakis et al., 2006;
Pinheiro et al., 2008a), cervical (Pinheiro et al., 2008b),
and breast carcinomas (Pinheiro et al., 2010). Besides
analysing MCT expression in tumours, our group also
assessed for the first time the clinico-pathological value
of their overexpression (Pinheiro et al., 2008a,b, 2009a,
2010). MCT expression appears to be influenced by
altered physiological conditions; however, the
underlying molecular events involved in MCT regulation
are poorly understood. Recently, it was demonstrated
that proper expression and activity of MCT1 and MCT4
requires co-expression of CD147, also known as
EMMPRIN or Basigin (Kirk et al., 2000; Wilson et al.,
2005). Based on this, we described the association
between CD147 and both MCT1 and MCT4 in human
cervical (Pinheiro et al., 2009b), gastric (Pinheiro et al.,
2009a) and breast cancer (Pinheiro et al., 2010).
Furthermore, the hypoxia inducible-factor 1 alpha (HIF-
1α), which regulates many genes codifying proteins
involved in the glycolytic pathway (like GLUT1) and pH
regulation (like the Na+/H+ exchanger NHE1 and both
CAIX and CAXII) (Vaupel and Harrison, 2004), also
regulates MCT1 (Perez et al., 2010) and MCT4 (Ullah et
al., 2006; Perez et al., 2010). However, there is some
controversy around MCT1 regulation by hypoxia, with
some studies reporting MCT1 repression by hypoxia
(Ullah et al., 2006; Sonveaux et al., 2008).
One of the goals of the present study was to evaluate
the association between the HIF-1α downstream targets
GLUT1 and CAIX and both MCT1 and MCT4, as well
as their chaperone, CD147, in invasive breast
carcinomas. We also intended to strengthen the clinico-
pathological value of GLUT1 and CAIX in breast
cancer.
Materials and methods
Case selection
Case selection was based on availability of follow up
information and amount of material, ensuring adequate
numbers for statistical analysis. Thus, a series of 124
formalin-fixed paraffin embedded breast carcinoma
tissues was retrieved from the files of the Department of
Pathology, Hospital do Divino Espírito Santo, Azores,
Portugal, and from the Federal University of Santa
Catarina, Florianopolis-SC, Brazil. Haematoxylin/eosin
stained sections of all cases were reviewed by three
pathologists (R.D., D.V. and F.S.). Tumour samples were
organized into 14 tissue microarrays (TMAs), with 20
tumour cores (2 mm diameter) each, also including
several samples of normal breast tissue. Each case was
represented in the TMA by at least two cores. Relevant
clinico-pathological data included tumour size (TNM),
molecular subtype, histological grade, estrogen receptor
(ER) and progesterone receptor (PR), human epidermal
growth factor receptor 2 (HER2), epidermal growth
factor receptor 1 (EGFR), basal cytokeratins (CK5 and
CK14), vimentin and Ki67 expression status.
Information on lymph-node metastasis, disease-free
survival and overall survival was also available. These
tumour samples were previously analysed by our group
for MCT1, MCT4 and CD147 expressions (Pinheiro et
al., 2010).
The molecular classification was done by translating
the immunohistochemistry results for ER, PR, HER2,
EGFR, CK5, CK14, vimentin and Ki-67. Tumours
positive for ER and/or PR were classified as luminal.
Cases positive for ER/PR and for HER2 and/or high Ki-
67 index were subclassified as luminal B. Cases
classified as HER2 overexpressing were characterized
by HER2 overexpression and negativity for ER/PR, and
cases defined as “basal-like” were negative for ER/PR
and HER2 and positive for at least one of the “basal
markers” tested.
Immunohistochemistry
GLUT1 and CAIX detection
Immunohistochemistry was performed based on the
streptavidin–biotin–peroxidase complex principle
(Ultravision Detection System Anti-polyvalent, HRP,
Lab Vision Corporation, Fremont, CA), using rabbit
polyclonal primary antibodies raised against GLUT1
(ab15309, AbCam, Cambridge, UK, diluted 1:500) and
CAIX (ab15086, AbCam, Cambridge, UK, diluted
1:2000). Briefly, deparaffinized and rehydrated sections
were immersed in citrate buffer (0.01M, pH 6.0) heated
up to 98ºC, in a water bath, for 10 minutes (GLUT1) or
20 minutes (CAIX) and washed in PBS. Endogenous
peroxidase activity was blocked with 3% hydrogen
peroxide in methanol for 10 minutes, followed by
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washing with PBS. Tissue sections were incubated with
blocking solution for 10 minutes and incubated at room
temperature with the primary antibody for 2 hours.
Sections were then sequentially washed in PBS and
incubated with biotinylated goat anti-polyvalent
antibody for 10 minutes, streptavidin peroxidase for 10
minutes, and developed with 3,3’-diamino-benzidine
(DAB+ Substrate System, Dako, Carpinteria, CA) for 10
minutes. Negative controls were performed by using
adequate serum controls for the primary antibodies
(N1699, Dako, Carpinteria, CA) and skin and gastric
mucosa were used as positive controls for GLUT1 and
CAIX, respectively. Tissue sections were counterstained
with haematoxylin and permanently mounted.
Immunohistochemical evaluation
As described for MCTs and CD147 (Pinheiro et al.,
2010), GLUT1 and CAIX immunohistochemical
reactions were scored semi-quantitatively for plasma
membrane staining as follows: 0: 0% of immunoreactive
cells; 1: <5% of immunoreactive cells; 2: 5-50% of
immunoreactive cells; and 3: >50% of immunoreactive
cells. Also, intensity of staining was scored semi-
qualitatively as follows: 0: negative; 1: weak; 2:
intermediate; and 3: strong. The final score was defined
as the sum of both parameters (extension and intensity),
and grouped as negative (score 0 and 2) and positive
(score 3-6). Evaluation of GLUT1 and CAIX
immunohistochemical reactions were performed blindly
by two independent observers (F.S., J.P.). Discordant
results between observers were discussed in a double-
head microscope and a final score was agreed, while
discordant results between different cores of the same
tumour were handled by choosing the highest staining
intensity and finding the mean value for immunoreactive
cells. 
Statistical analysis
Data were stored and analysed using the Statview
statistical software (SAS Institute Inc., Cary, NC). All
comparisons were examined for statistical significance
using Pearson’s chi-square (χ2) test or Fisher’s exact
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Fig. 1. Immunohistochemcial expression of glucose transporter 1 (GLUT1), carbonic anhydrase IX (CAIX) and monocarboxylate transporter 1 (MCT1),
in breast carcinoma samples. GLUT1 and CAIX expression was frequently observed in perinecrotic regions (A and B, respectively). CAIX expression
was usually focal and mainly restricted to tumour cells. Lower panel shows a breast ancer case simultaneously positive for MCT1 (C), GLUT1 (D) and
CAIX (E), with staining in the same tumour region.
test, as appropriate, the threshold for significance p
values being <0.05. Disease-free and overall survival
curves were plotted using the method of Kaplan-Meier
and data were compared using the log-rank test. The first
5 years following primary therapy was considered
because recurrence rates are expected to be highest in
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Table 1. Association of CAIX and GLUT1 with MCT1, MCT4 and CD147 expression in breast carcinoma samples.
n MCT1 Positive (%) p MCT4 Positive (%) p CD147 Positive (%) p
GLUT1 106 <0.0001 0.3473 0.0032
Negative 55 1 (1.8) 4 (7.3) 2 (3.6)
Positive 51 15 (29.4) 7 (13.7) 12 (23.5)
CAIX 105 <0.0001 0.6897 0.0005
Negative 84 6 (7.1) 8 (9.5) 7 (8.3)
Positive 21 10 (47.6) 3 (14.3) 8 (38.0)
Table 2. Associations of CAIX and GLUT1 expression with clinico-pathological data from breast cancer cases.
Clinico-pathological data GLUT1 CAIX
n Positive (%) p n Positive (%) p
T size (TNM) 121 0.5218 119 0.0034
T1 46 23 (50.0) 45 6 (13.3)
T2 63 25 (39.7) 63 9 (14.3)
T3 12 6 (50.0) 11 6 (54.5)
Histological grade 124 0.0014 122 0.0263
I 23 5 (21.7) 24 2 (8.3)
II 55 22 (40.0) 51 6 (11.8)
III 46 30 (65.2) 47 14 (29.8)
Subtype 114 0.0008 113 0.0050
Luminal 78 31 (39.7) 79 8 (10.1)
Basal-like 25 20 (80.0) 24 9 (37.5)
HER2 overexpressing 11 3 (27.3) 10 3 (30.0)
Estrogen receptor 124 0.1059 122 0.0014
Negative 45 25 (55.6) 42 14 (33.3)
Positive 79 32 (40.5) 80 8 (10.0)
Progesterone receptor 124 0.0162 122 0.0292
Negative 75 41 (54.7) 73 18 (24.6)
Positive 49 16 (32.6) 49 4 (8.2)
HER2 overexpression 123 0.5885 121 0.4556
Negative 110 51 (46.4) 109 19 (17.4)
Positive 13 5 (38.5) 12 3 (25.0)
EGFR 124 >0.9999 122 0.6643
Negative 115 53 (46.1) 113 20 (17.7)
Positive 9 4 (44.4) 9 2 (22.2)
CK5 124 0.1188 122 0.0002
Negative 98 42 (42.8) 97 11 (11.3)
Positive 26 15 (57.7) 25 11 (44.0)
CK14 121 0.0508 121 0.0102
Negative 114 51 (44.7) 115 18 (15.6)
Positive 7 6 (85.7) 6 4 (66.7)
Vimentin 106 0.0033 106 0.0004
Negative 89 38 (42.7) 88 12 (13.6)
Positive 17 14 (82.4) 18 9 (50.0)
Ki67 124 0.0339 122 0.5214
< 20% 65 24 (36.9) 63 10 (15.9)
> 20% 59 33 (55.9) 59 12 (20.3)
Lymph-node metastasis 117 0.6326 115 0.5840
Absent 58 24 (41.4) 55 8 (14.5)
Present 59 27 (45.8) 60 11 (18.3)
this period of time, especially in series with high number
of ER negative cases like the one herein studied (Emens
and Davidson, 2003). Cases lacking one or more of the
clinico-pathological variables were not included in the
specific statistical analysis.
Results
A total of 124 breast carcinoma samples, organised
into TMAs (Tissue Microarrays), were assessed for
GLUT1 and CAIX immunohistochemical expressions. 
In general, positive GLUT1 expression was
observed in both plasma membrane and cytoplasm (Fig.
1A), while CAIX expression was mainly observed in the
plasma membrane, with some cases also presenting
cytoplasm staining (Fig. 1B). GLUT1 expression was
observed only in the epithelial cells of 1 out of 20
normal samples evaluated (5%), with a significantly
higher frequency (46%) in tumour samples (57/124,
p=0.0005), while CAIX expression was absent in normal
tissue but was found in 18% (22/122) of breast cancer
cases (p=0.0388). Importantly, the expression of both
molecules was frequently observed in perinecrotic
regions, as can be observed in Figure 1A,B, especially
CAIX, which was usually focal and mainly restricted to
tumour cells adjacent to areas of necrosis.
Importantly, when comparing the expression of the
previously analysed MCT1, MCT4 and CD147 (Pinheiro
et al., 2010) with GLUT1 and CAIX, we found that both
MCT1 and CD147, but not MCT4, were more frequently
expressed in GLUT1 and CAIX positive tumour samples
(Table 1). Also, as expected, GLUT1 and CAIX were
significantly co-expressed, with 81.8% (18/22) of CAIX
positive cases also positive for GLUT1, versus 37.5%
(36/96) GLUT1 positive in the CAIX negative group,
p=0.0002. Figure 1C-E shows a breast cancer case
simultaneously positive for MCT1, GLUT1 and CAIX,
in the same tumour area.
Assessment of the clinico-pathological value of
GLUT1 and CAIX also retrieved important results
(Table 2). We found significant associations between
GLUT1 expression and high grade tumours (p=0.0014),
basal-like subtype (p=0.0008), absence of PR
(p=0.0162), presence of vimentin (p=0.0033) and high
proliferative index as measured by Ki67 expression
(p=0.0339). Additionally, CAIX was associated with the
majority of the clinico-pathological parameters analysed,
including tumour size (p=0.0034), histological grade
(p=0.0263), molecular subtype (p=0.0050), ER and PR
negativity (p=0.0014 and p=0.0292, respectively),
expression of CK5 (p=0.0002), CK14 (p=0.0102) and
vimentin (p=0.0004). 
Analysis of GLUT1 expression and patients’
survival (disease-free survival and overall survival)
showed no significant differences between negative and
positive groups (data not shown), but, importantly,
patients with CAIX positive tumours had a lower
disease-free survival than patients with CAIX negative
tumours (43.2 versus 52.4 months, respectively,
p=0.045) (Fig. 2). No significant differences in overall
survival were observed between the CAIX negative
group and the CAIX positive group.
Discussion
Upregulation of glucose conversion into lactate,
even in the presence of oxygen (Warburg effect), has
been described as a possible adaptive mechanism to
overcome intermittent hypoxia in pre-malignant lesions.
This metabolic switch leads to an increase in acid
production by cancer cells and, therefore, the need for
further adaptation by means of intracellular pH
regulation and resistance to extracellular acidity
(Gatenby and Gilles, 2004). In this perspective, MCTs
emerge as important contributors to cancer cell
adaptation due to their function, on one hand, of lactate
export, allowing continuous glycolysis, and, on the other
hand, of tumour intracellular pH regulation and
induction of extracellular acidosis, by co-transporting
lactate and a proton. Although the contribution of MCTs
to the glycolytic and acidic phenotype of tumours is
suggested (Mathupala et al., 2007), the significance of
tumour MCT expression in this context is still not clear.
Thus, the main aim of the present work was to determine
whether glycolytic and acid-resistant tumours, with
upregulation of GLUT1 and CAIX, present a higher
expression of MCTs, supporting the involvement of
these transporters in the metabolic adaptations of cancer
cells.
GLUT1, involved in glucose uptake, is upregulated
in a variety of tumours (for a review see Macheda et al.,
2005), being the hypoxia transcription factor HIF-1α the
major regulator of its expression in cancer cells
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Fig. 2. Disease-free survival (DFS) curve regarding CAIX
immunoreaction in breast cancer patients. Patients with positive
tumours for CAIX expression show shorter disease-free survival
(interrupted line) than patients with CAIX negative tumours (continuous
line) (p=0.045).
(Baumann et al., 2007). HIF-1α, the master
transcriptional regulator of tumour cell adaptation to
hypoxic stress, activates a number of genes, many of
which code for proteins involved in O2 delivery,
angiogenesis, energy preservation (including glucose
transporters and glycolytic enzymes), and other
processes essential to tumour cell survival, proliferation,
and spread (Vaupel and Harrison, 2004). Moreover,
CAIX and MCT4 are also downstream targets of HIF-1α
(Wykoff et al., 2000; Ullah et al., 2006; Perez et al.,
2010) and both GLUT1 and CAIX are recognised as
tumour hypoxia markers (Vordermark and Brown,
2003). However, in our study, MCT4 expression was not
increased in GLUT1 or CAIX positive tumours. In
contrast, MCT1 was more frequently expressed in both
GLUT1 and CAIX positive tumours, pointing to a
hypoxia dependent upregulation of this MCT isoform,
which is accompanied by co-expression of its chaperone
CD147, essential for plasma membrane localization and
transporter activity (Kirk et al., 2000; Wilson et al.,
2005). This finding is of major importance since it
supports the induction of MCT1 expression by hypoxia
(Perez et al., 2010), which is contested by some groups
(Ullah et al., 2006; Sonveaux et al., 2008). With these
associations, one can support the role of functional
MCT1 as the lactate transporter responsible for lactate
efflux in highly glycolytic breast cancer cells, especially
in basal-like tumours. The transport activity of MCT1 is
considered one of the most important mechanisms of
intracellular pH regulation (Izumi et al., 2003). Besides
MCTs, carbonic anhydrases, especially CAIX, play a
major role in maintenance of intracellular (and
extracellular) pH levels, by contributing to the extrusion
of the protons generated by the high metabolic rates of
glycolytic cancer cells. At the tumour cell surface, CAIX
catalyses the extracellular trapping of acid, by hydrating
the cell-generated CO2 into HCO3- and H+ (Swietach et
al., 2007). Thus, it is not surprising to see an association
between MCT1 and both GLUT1 and CAIX, which is
likely a result of the overall HIF-1α-mediated metabolic
adaptations, conferring a glycolytic, acid-resistant
phenotype to cancer cells. 
As described previously (Chia et al., 2001; Vleugel
et al., 2005), GLUT1 and CAIX were mainly observed
in the vicinity of necrotic areas (a consequence of
tumour hypoxia) in our tumour series, which supports
the hypoxia-mediated regulation of the expression of
these proteins. Both hypoxia markers were absent in
normal breast tissue, but upregulated in breast tumour
tissues, with expression frequencies concordant with
previous reports (Kang et al., 2002; Younes et al., 1995;
Hussain et al., 2007; Trastour et al., 2007; Tan et al.,
2009; Chen et al., 2010). Although the clinico-
pathological value of GLUT1 and CAIX in breast cancer
has already been studied by others (Chia et al., 2001;
Younes et al., 1995; Hussain et al., 2007; Trastour et al.,
2007; Tan et al., 2009), our data strengthens the
importance of these proteins as prognostic markers,
especially GLUT1, which has been little explored in
breast cancer (Kang et al., 2002; Younes et al., 1995;
Chen et al., 2010). So far, GLUT1 has been associated
with lower disease-free survival, loss of ER and PR
(Kang et al., 2002) and both higher grade (Kang et al.,
2002; Younes et al., 2005; Chen et al., 2010) and
proliferative activity (through Ki67 expression) (Younes
et al., 1995). In the present work, although we did not
find associations of GLUT1 with disease-free or overall
survival, GLUT1 was more frequently expressed in high
grade tumours, negative for PR and with high
proliferative index (Ki67). Importantly, we found
GLUT1 to be more frequently expressed in basal-like
tumours, as well as in vimentin positive tumours. With
respect to CAIX, more data has been published in breast
carcinomas, which identifies CAIX as a marker of
aggressive tumour behaviour. This protein was
positively correlated with larger tumour size, basal-like
(Tan et al., 2009) and high grade tumours (Chia et al.,
2001; Span et al., 2003; Trastour et al., 2007; Tan et al.,
2009, Chen et al., 2010), loss of ER (Chia et al., 2001;
Span et al., 2003; Trastour et al., 2007; Tan et al., 2009)
and PR (Span et al., 2003) as well as with shorter
disease-free survival (Chia et al., 2001; Hussain et al.,
2007; Tan et al., 2009). Here, we support all the previous
findings described by other groups, by associating CAIX
expression with high histological grade, loss of ER and
PR and, importantly, basal-like subtype and disease-free
survival. These results suggest that the basal-like
subtype tumours may be more representative of the
glycolytic, acid-resistant phenotype proposed for cancer
cells and this hypoxia mediated phenotype may explain,
at least partly, the more aggressive phenotype of this
breast carcinoma subtype.
In the present study, we investigated the expression
of the key hypoxia regulated proteins GLUT1 and
CAIX. Importantly, they were positively associated with
the major lactate transporter, MCT1, especially in a
subset of aggressive breast carcinomas (basal-like),
where these proteins are more frequently expressed.
Since this subtype of tumours does not have a specific
molecular therapy (Matos et al., 2005), the development
of therapeutic approaches targeting these particular
metabolic features could be a promising strategy to be
explored in the treatment of basal-like breast tumours. 
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